Glucose, blood pressure, and cardiovascular risk

Circulation: Cardiovascular Quality and Outcomes

Volumn 5, Issue 2, 2012, Pages 145-147

  Lleva, Ranee R ^a   Inzucchi, Silvio E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antihypertensive agents; Cardiovascular risk; Diabetes; Editorials

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; LISINOPRIL; THIAZIDE DIURETIC AGENT;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DYSGLYCEMIA; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; MALE; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84860859073     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.112.965046     Document Type: Review

References (19)

1. Hansen MB, Jensen ML, Cartensen B. Causes of death among diabetic patients in Denmark. Diabetologia. 2012;55:294-302.
2. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent? results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care. 2005;28: 1588-1593. (Pubitemid 40923069)
3. Carnethon MR, Biggs ML, Barzilay J, Kuller LH, Mozaffarian D, Mukamal K, Smith NL, Siscovick D. Diabetes and coronary heart disease as risk factors for mortality in older adults. Am J Med. 2010;123: 556.e1-559.e1.
4. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? systematic review and meta-Analysis. Diabet Med. 2009;26:142-148.
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
6. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119:351-357.
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
8. Whaley-Connell A, Sowers JR. Hypertension and insulin resistance. Hypertension. 2009;54:462-464.
9. Hypertension in Diabetes Study II: Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens. 1993;11: 319-325.
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703-713.
11. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomized controlled trial. Lancet. 2007;370:829-840.
12. Hannson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762. (Pubitemid 28269185)
13. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3-10. (Pubitemid 41819128)
14. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care. 2004;27:247-255. (Pubitemid 38196740)
15. Asfaha S, Padwal R. Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice. Curr Hypertens Rep. 2005;7:314-322. (Pubitemid 41535769)
16. Levine M, Boyer EW, Pozner CN, Geib AJ, Thomsen T, Mick N, Thomas SH. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007;35: 2071-2075. (Pubitemid 47326443)
17. American Diabetes Association. Standards of Medical Care 2012. Diab Care. 2012;35:S11-S63.
18. Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, Cushman WC, Ford CE, Margolis KL, Moloo J, Oparil S, Piller LB, Simmons DL, Sweeney ME, Whelton PK, Wong ND, Jackson T; ALLHAT Collaborative Research Group. Long-Term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: The ALLHAT diabetes extension study. Circ Cardiovasc Qual Outcomes. 2012;5:153-162.
19. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC Study Research Group). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.